
Patients With Multiple Types of Mismatch Repair–Deficient Tumors Avoid Surgery With Dostarlimab
Patients with multiple types of locally advanced, mismatch repair–deficient (dMMR) tumors were able to avoid surgery following treatment with the PD-1 inhibitor dostarlimab (Jemperli, GSK) according to updated data being presented today at the American …